The results of a new study conducted by AARP show that pharmaceutical prices for brand name products has increased drastically. Read More »

Endo International subsidiary Par Pharmaceutical has begun the shipping process for ezetimibe 10 mg tablets, which is the generic form of ZETIA, developed by Merck. Read More »

EMD Serono, subsidiary of Merck KGaA, has appointed Brian Barry as its chief compliance officer with oversight of the development and execution of EMD Serono’s comprehensive compliance program. Read More »

Legislators in Missouri will move in the next session to bring the state into line with most of the rest of the country by heightening the standard on expert witness testimony in civil trials. Read More »

Protagen AG has launched NavigAID SSc, its disease stratification assay that was developed to assist pharmaceutical and biotechnology companies with their efforts to develop drugs to treat Systemic Sclerosis. Read More »

Bayer's supplemental Biologics License Application (sBLA) for myBETAapp and the BETACONNECT Navigator has been accepted by the U.S. Food and Drug Administration. Read More »

Castle Creek Pharmaceuticals' exclusive license agreement for the rights to Arlevert in the United States has been finalized. Read More »

Express Scripts' enhancements have been applied to its SafeGuardRx programs, which focus on the treatment of hepatitis C and cancer. Read More »

AcelRx Pharmaceuticals has submitted a New Drug Application for ARX-04 (sufentanil sublingual tablet, 30 mcg) to the U.S. Food and Drug Administration. Read More »

aTyr Pharma has released results of its exploratory clinical trials designed to evaluate the safety and potential activity of Resolaris in treating LGMD2B and FSHD. Read More »

Cognition Therapeutics has initiated testing of CT1812 in clinical trials in the United States. Read More »

CVS Health has launched Transform Diabetes Care, its new program set up to assist pharmacy benefits management clients in the improvement of member health outcomes, to decrease costs with aggressive trend management, and to cut medical costs by refining medication adherence. Read More »

Merck recently released KEYTRUDA data demonstrating an overall response rate of 41 percent in patients with relapsed or refractory primary mediastinal large B-cell lymphoma. Read More »

Merck continued its release of KEYTRUDA results by reporting that its Phase 3 KEYNOTE-024 clinical trial demonstrated positive health-related quality of life. Read More »

A Walgreens study conducted in collaboration with the Scripps Translational Science Institute demonstrated that long-term health engagement can be meaningfully improved by automated health tracking. Read More »

Eiger BioPharmaceuticals has announced clinical and regulatory development advancements of exendin 9-39, which was developed to treat post-bariatric hypoglycemia. Read More »

Teva Pharmaceuticals Industries has appointed Dipanker Bhattacharjee president and CEO of its Global Generic Medicines Group, effective immediately. Read More »

Merck has released updated data from two clinical trials designed to assess KEYTRUDA (pembrolizumab), its anti-PD-1 therapy developed to treat patients who have relapsed or refractory classical Hodgkin lymphoma (cHL). Read More »

Merck recently released updated data from its Phase 1b KEYNOTE-028 clinical trial, which involved KEYTRUDA. Read More »

Endo International plc subsidiary Par Pharmaceutical has released mycophenolate mofetil hydrochloride as an injection in the United States after the Food and Drug Administration gave its approval of Endo’s Abbreviated New Drug Application. Read More »